SCHEMBL240725

SCHEMBL240725

CC(C)(C)OC(=O)CN=C(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.48
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PTPRC P08575 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 1/20 0.39
CYP2C19 P33261 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
HIF1A Q16665 1/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
SLC7A5 Q01650 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL478673 0.81 TSHR (0.48) ALDH1A1HSD17B10CYP1A2CYP2D6TSHR
SCHEMBL17003212 0.80 PRSS1 (0.44) ALDH1A1HSD17B10CYP1A2CYP2D6TSHR
SCHEMBL15721458 0.80 AAK1 (0.42) AAK1ALDH1A1HSD17B10CYP1A2CYP2D6
SCHEMBL17723 0.78 GAA (0.52) ALDH1A1HSD17B10CYP1A2CYP2D6TSHR
SCHEMBL9669310 0.78 CYP3A4 (0.49) ALDH1A1CYP1A2CYP2D6CYP2C19NPSR1
SCHEMBL13398132 0.77 CYP1A2 (0.42) ALDH1A1HSD17B10CYP1A2CYP2D6TSHR
SCHEMBL12690674 0.77 AAK1 (0.41) AAK1ALDH1A1HSD17B10CYP1A2CYP2D6
SCHEMBL12092169 0.77 AAK1 (0.41) AAK1ALDH1A1HSD17B10CYP1A2CYP2D6
SCHEMBL16658953 0.77 TSHR (0.53) ALDH1A1HSD17B10CYP1A2CYP2D6TSHR
Methane SCHEMBL28846175 0.77 GAA (0.51) ALDH1A1HSD17B10CYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 846 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005531-A Synthesis method of chiral unnatural amino acid derivative 内蒙古大学 2024-05-10 CN claimed
CN-115260126-B Chiral quaternary ammonium salt with (S) -binaphthyl, preparation method and application 湖南城市学院 2024-01-30 CN claimed
CN-115260126-A Chiral quaternary ammonium salt with (S) -binaphthyl and preparation method and application thereof 湖南城市学院 2022-11-01 CN claimed
CN-114262295-A Chiral quaternary ammonium salt with spiro indane skeleton and its prepn and application 天津大学 2022-04-01 CN claimed
CN-108299482-B F-BPA and intermediate synthesis method, intermediate and application thereof 中国原子能科学研究院 2020-10-09 CN claimed
CN-104263795-A Method for preparing chiral alpha-naphthenic glycine SICHUAN TONGSHENG BIOTECHNOLOGY CO LTD 2015-01-07 CN claimed
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-10-02 US claimed
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-11-08 US claimed
US-20120064034-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 US claimed
US-20110178302-A1 NUCLEOPHILIC FLUORINATION OF AROMATIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-07-21 US claimed
JP-4689938-B2 2011-06-01 JP claimed
EP-2307337-A2 NUCLEOPHILIC FLUORINATION OF AROMATIC COMPOUNDS The Regents Of The University Of California (US) 2011-04-13 EP claimed
EP-1878720-B1 Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors VERTEX PHARMA (US) 2010-10-06 EP claimed
US-20100137583-A1 Peptidomimetic protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2010-06-03 US claimed
WO-2010008522-A2 NUCLEOPHILIC FLUORINATION OF AROMATIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-01-21 WO claimed
EP-1878720-A1 Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors Vertex Pharmaceuticals Incorporated (US) 2008-01-16 EP claimed
US-20050197299-A1 Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives VERTEX PHARMACEUTICALS INCORPORATED 2005-09-08 US claimed
JP-2004517047-A 2004-06-10 JP claimed
EP-1320540-A2 PEPTIDOMIMETIC PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2003-06-25 EP claimed
WO-2002018369-A2 PEPTIDOMIMETIC PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-03-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197299-A1 Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives CTRC, PEPD, CTSC AAK1 2545/4885ALDH1A1 1451/4885HSD17B10 1793/4885
US-20140294763-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PREP, PEPD AAK1 3561/4885ALDH1A1 2218/4885HSD17B10 2139/4885
US-20100137583-A1 Peptidomimetic protease inhibitors CTSC, PREP, PEPD AAK1 3561/4885ALDH1A1 2218/4885HSD17B10 2139/4885
US-20120064034-A1 Peptidomimetic protease inhibitors CTSC, PREP, PEPD AAK1 3561/4885ALDH1A1 2218/4885HSD17B10 2139/4885
US-20110178302-A1 NUCLEOPHILIC FLUORINATION OF AROMATIC COMPOUNDS SLC18A2, AFF4, SLC6A19 AAK1 4518/4885ALDH1A1 2811/4885HSD17B10 3677/4885
US-20120282219-A1 PEPTIDOMIMETIC PROTEASE INHIBITORS CTSC, PEPD, PREP AAK1 3217/4885ALDH1A1 2639/4885HSD17B10 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.